Increasing HPV vaccination in young cancer survivors
Increasing HPV Vaccination Coverage Among Pediatric, Adolescent, and Young Adult (PAYA) Cancer Survivors: A Multilevel Intervention
This study is trying to see if a new approach using doctors and a helpful app can get young cancer survivors to start and finish their HPV vaccinations to protect them from future cancers.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 490 (estimated) |
| Ages | 9 Years to 26 Years |
| Sex | All |
| Sponsor | Masonic Cancer Center, University of Minnesota Academic / other |
| Locations | 1 site (Minneapolis, Minnesota) |
| Trial ID | NCT05665543 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance the initiation and completion of the HPV vaccination series among pediatric, adolescent, and young adult cancer survivors. Given that these survivors are at a significantly higher risk for developing secondary HPV-associated cancers, the study will implement an oncologist- and clinic-level intervention alongside a patient-level app-based intervention. The goal is to provide better information and support regarding HPV vaccination, which is often overlooked in cancer care. By addressing the gaps in communication and education, the study seeks to improve vaccination rates in this vulnerable population.
Who should consider this trial
Good fit: Ideal candidates include pediatric, adolescent, and young adult cancer survivors aged 18-26, or caregivers of survivors aged 9-17, who are at least 6 months post-treatment and have not received the HPV vaccine.
Not a fit: Patients who have already completed the HPV vaccination series or those who are not currently receiving care at the specified clinics may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly reduce the incidence of secondary HPV-associated cancers in young cancer survivors.
How similar studies have performed: Other studies have shown that targeted interventions can improve vaccination rates in at-risk populations, suggesting a potential for success with this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Current patient in the University of Minnesota CCSP clinic or the Children's Minnesota Long-Term Follow-up (LTFU) Program clinic. * Patients seen in the CCSP clinic who do not have a history of cancer but who have received immunosuppressive therapy or HSCT for treatment of a hematologic disorder. * Survivor of childhood cancer (defined as diagnosed with cancer at age 25 years or younger) who is currently 18-26 years of age OR a caregiver of a survivor of childhood cancer who is currently 9-17 years of age. * 6+ months post-treatment; current treatment for graft-versus-host disease allowed * No previous HPV vaccination or incomplete HPV vaccination (defined as \<3 doses post-cancer therapy). Individuals who are unsure of their HPV vaccination status who are unable to find vaccination records per the procedures detailed in Section 5.2, EHR support will be eligible, in concordance with real-world clinical practice regarding HPV vaccination. Exclusion Criteria: * Previous completion of the HPV vaccination series. Those who are eligible for re-vaccination per the CDC guidelines will be encouraged by their oncologist to re-vaccinate, but will not be included in the QI study or RCT. * Unable to read/write in English per self-report (only applies to participants in the RCT \[Aim 2\]). * Pregnant at the time of enrollment or plans to become pregnant in the next year. Pregnancy test at the time of enrollment is not required if pregnancy not clinically suspected in concordance with clinical guidelines for HPV vaccine administration. * Currently receiving treatment for cancer or hematologic disorder or plan for treatment within 12 months of enrollment; treatment for graft-versus-host disease allowed. * Other contraindications to the HPV vaccine (e.g. history of immediate hypersensitivity reaction to any vaccine component, including yeast).
Where this trial is running
Minneapolis, Minnesota
- University of Minnesota Masonic Cancer Center — Minneapolis, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Deanna Teoh, MD, MS — Masonic Cancer Center, University of Minnesota
- Study coordinator: Deanna Teoh, MD, MS
- Email: dkteoh@umn.edu
- Phone: 612-625-6503
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.